nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—EPHB4—breast cancer	0.119	0.271	CbGaD
Nilotinib—MAPK8—breast cancer	0.0795	0.181	CbGaD
Nilotinib—CSF1R—breast cancer	0.0519	0.118	CbGaD
Nilotinib—ABL1—breast cancer	0.0404	0.0918	CbGaD
Nilotinib—BRAF—breast cancer	0.0404	0.0918	CbGaD
Nilotinib—KIT—breast cancer	0.0324	0.0737	CbGaD
Nilotinib—CA9—breast cancer	0.0311	0.0708	CbGaD
Nilotinib—ABCG2—breast cancer	0.0179	0.0408	CbGaD
Nilotinib—CYP2B6—Thiotepa—breast cancer	0.0119	0.051	CbGbCtD
Nilotinib—CYP2D6—breast cancer	0.0105	0.0238	CbGaD
Nilotinib—UGT1A1—Irinotecan—breast cancer	0.0104	0.0447	CbGbCtD
Nilotinib—CYP3A4—breast cancer	0.00896	0.0204	CbGaD
Nilotinib—CYP2C9—Anastrozole—breast cancer	0.00827	0.0356	CbGbCtD
Nilotinib—CYP2B6—Raloxifene—breast cancer	0.00792	0.0341	CbGbCtD
Nilotinib—CYP2C8—Lapatinib—breast cancer	0.00791	0.034	CbGbCtD
Nilotinib—ABCB1—breast cancer	0.00746	0.017	CbGaD
Nilotinib—ABCG2—Tamoxifen—breast cancer	0.00744	0.032	CbGbCtD
Nilotinib—ABCB1—Toremifene—breast cancer	0.00734	0.0316	CbGbCtD
Nilotinib—ABCG2—Mitoxantrone—breast cancer	0.00726	0.0312	CbGbCtD
Nilotinib—CYP3A4—Exemestane—breast cancer	0.00635	0.0273	CbGbCtD
Nilotinib—CYP2C9—Idarubicin—breast cancer	0.00627	0.027	CbGbCtD
Nilotinib—CYP2C8—Raloxifene—breast cancer	0.006	0.0258	CbGbCtD
Nilotinib—ABCG2—Paclitaxel—breast cancer	0.00579	0.0249	CbGbCtD
Nilotinib—CYP2D6—Idarubicin—breast cancer	0.00573	0.0247	CbGbCtD
Nilotinib—ABCG2—Irinotecan—breast cancer	0.00571	0.0246	CbGbCtD
Nilotinib—ABCG2—Fluorouracil—breast cancer	0.00548	0.0236	CbGbCtD
Nilotinib—ABCG2—Carboplatin—breast cancer	0.00545	0.0234	CbGbCtD
Nilotinib—CYP3A4—Letrozole—breast cancer	0.0054	0.0232	CbGbCtD
Nilotinib—ABCB1—Lapatinib—breast cancer	0.00536	0.023	CbGbCtD
Nilotinib—CYP2B6—Tamoxifen—breast cancer	0.00523	0.0225	CbGbCtD
Nilotinib—CYP3A4—Anastrozole—breast cancer	0.00481	0.0207	CbGbCtD
Nilotinib—CYP3A4—Toremifene—breast cancer	0.0044	0.0189	CbGbCtD
Nilotinib—ABCG2—Docetaxel—breast cancer	0.00419	0.018	CbGbCtD
Nilotinib—CYP3A4—Fulvestrant—breast cancer	0.00409	0.0176	CbGbCtD
Nilotinib—CYP2B6—Irinotecan—breast cancer	0.00402	0.0173	CbGbCtD
Nilotinib—CYP2C8—Tamoxifen—breast cancer	0.00396	0.017	CbGbCtD
Nilotinib—CYP3A4—Thiotepa—breast cancer	0.00365	0.0157	CbGbCtD
Nilotinib—CYP2C9—Capecitabine—breast cancer	0.00344	0.0148	CbGbCtD
Nilotinib—CYP3A4—Ixabepilone—breast cancer	0.00333	0.0143	CbGbCtD
Nilotinib—CYP3A4—Lapatinib—breast cancer	0.00321	0.0138	CbGbCtD
Nilotinib—ABCG2—Doxorubicin—breast cancer	0.00312	0.0134	CbGbCtD
Nilotinib—CYP2C8—Paclitaxel—breast cancer	0.00308	0.0133	CbGbCtD
Nilotinib—ABCG2—Methotrexate—breast cancer	0.00302	0.013	CbGbCtD
Nilotinib—ABCB1—Vinorelbine—breast cancer	0.00297	0.0128	CbGbCtD
Nilotinib—CYP2C8—Fluorouracil—breast cancer	0.00292	0.0126	CbGbCtD
Nilotinib—CYP2D6—Vinorelbine—breast cancer	0.0028	0.012	CbGbCtD
Nilotinib—CYP2C9—Tamoxifen—breast cancer	0.00276	0.0119	CbGbCtD
Nilotinib—ABCB1—Tamoxifen—breast cancer	0.00268	0.0115	CbGbCtD
Nilotinib—ABCB1—Mitoxantrone—breast cancer	0.00262	0.0113	CbGbCtD
Nilotinib—CYP2D6—Tamoxifen—breast cancer	0.00253	0.0109	CbGbCtD
Nilotinib—CYP3A4—Raloxifene—breast cancer	0.00243	0.0105	CbGbCtD
Nilotinib—ABCB1—Gemcitabine—breast cancer	0.00231	0.00994	CbGbCtD
Nilotinib—CYP2B6—Doxorubicin—breast cancer	0.00219	0.00944	CbGbCtD
Nilotinib—CYP2C9—Paclitaxel—breast cancer	0.00215	0.00925	CbGbCtD
Nilotinib—ABCB1—Paclitaxel—breast cancer	0.00209	0.00898	CbGbCtD
Nilotinib—ABCB1—Irinotecan—breast cancer	0.00206	0.00886	CbGbCtD
Nilotinib—CYP2C9—Fluorouracil—breast cancer	0.00204	0.00876	CbGbCtD
Nilotinib—ABCB1—Vinblastine—breast cancer	0.00183	0.00788	CbGbCtD
Nilotinib—CYP3A4—Vinorelbine—breast cancer	0.00178	0.00766	CbGbCtD
Nilotinib—CYP2D6—Vinblastine—breast cancer	0.00173	0.00742	CbGbCtD
Nilotinib—CYP3A4—Tamoxifen—breast cancer	0.00161	0.00691	CbGbCtD
Nilotinib—CYP3A4—Mitoxantrone—breast cancer	0.00157	0.00674	CbGbCtD
Nilotinib—ABCB1—Docetaxel—breast cancer	0.00151	0.00649	CbGbCtD
Nilotinib—CYP3A4—Paclitaxel—breast cancer	0.00125	0.00538	CbGbCtD
Nilotinib—CYP3A4—Irinotecan—breast cancer	0.00123	0.00531	CbGbCtD
Nilotinib—ABCB1—Doxorubicin—breast cancer	0.00113	0.00484	CbGbCtD
Nilotinib—CYP3A4—Vinblastine—breast cancer	0.0011	0.00472	CbGbCtD
Nilotinib—ABCB1—Methotrexate—breast cancer	0.00109	0.00469	CbGbCtD
Nilotinib—CYP2D6—Doxorubicin—breast cancer	0.00106	0.00456	CbGbCtD
Nilotinib—CYP3A4—Docetaxel—breast cancer	0.000904	0.00389	CbGbCtD
Nilotinib—CYP3A4—Doxorubicin—breast cancer	0.000674	0.0029	CbGbCtD
Nilotinib—Ponatinib—FGFR2—breast cancer	0.000463	0.117	CrCbGaD
Nilotinib—Ponatinib—FGFR1—breast cancer	0.000463	0.117	CrCbGaD
Nilotinib—ABL1—Topotecan—Irinotecan—breast cancer	0.000427	0.257	CbGdCrCtD
Nilotinib—Imatinib—NQO2—breast cancer	0.000382	0.0969	CrCbGaD
Nilotinib—Ponatinib—ABL1—breast cancer	0.000326	0.0827	CrCbGaD
Nilotinib—Ponatinib—SRC—breast cancer	0.000295	0.0748	CrCbGaD
Nilotinib—Ponatinib—KDR—breast cancer	0.000277	0.0703	CrCbGaD
Nilotinib—TIE1—female reproductive system—breast cancer	0.000269	0.00432	CbGeAlD
Nilotinib—PDGFRA—embryo—breast cancer	0.000267	0.00429	CbGeAlD
Nilotinib—MAP4K1—bone marrow—breast cancer	0.000266	0.00427	CbGeAlD
Nilotinib—MAPK14—epithelium—breast cancer	0.000265	0.00426	CbGeAlD
Nilotinib—MAPK8—endocrine gland—breast cancer	0.000262	0.00422	CbGeAlD
Nilotinib—EPHA6—endocrine gland—breast cancer	0.000262	0.00422	CbGeAlD
Nilotinib—TIE1—adrenal gland—breast cancer	0.000262	0.00422	CbGeAlD
Nilotinib—Ponatinib—KIT—breast cancer	0.000262	0.0664	CrCbGaD
Nilotinib—HCK—uterus—breast cancer	0.000261	0.0042	CbGeAlD
Nilotinib—KIT—nipple—breast cancer	0.000259	0.00416	CbGeAlD
Nilotinib—Imatinib—CSF1R—breast cancer	0.000258	0.0655	CrCbGaD
Nilotinib—HCK—pituitary gland—breast cancer	0.000257	0.00412	CbGeAlD
Nilotinib—EPHB3—female reproductive system—breast cancer	0.000256	0.00411	CbGeAlD
Nilotinib—HCK—adipose tissue—breast cancer	0.000256	0.00411	CbGeAlD
Nilotinib—ABL2—pituitary gland—breast cancer	0.000255	0.0041	CbGeAlD
Nilotinib—ABL2—adipose tissue—breast cancer	0.000254	0.00408	CbGeAlD
Nilotinib—PDGFRB—nipple—breast cancer	0.000253	0.00406	CbGeAlD
Nilotinib—MAPK14—skin of body—breast cancer	0.000252	0.00405	CbGeAlD
Nilotinib—BRAF—adrenal gland—breast cancer	0.000252	0.00404	CbGeAlD
Nilotinib—EPHB4—epithelium—breast cancer	0.000251	0.00404	CbGeAlD
Nilotinib—EPHB3—adrenal gland—breast cancer	0.00025	0.00401	CbGeAlD
Nilotinib—EPHA2—epithelium—breast cancer	0.000247	0.00396	CbGeAlD
Nilotinib—TIE1—female gonad—breast cancer	0.000245	0.00393	CbGeAlD
Nilotinib—BRAF—bone marrow—breast cancer	0.000243	0.00391	CbGeAlD
Nilotinib—LYN—endocrine gland—breast cancer	0.000242	0.00389	CbGeAlD
Nilotinib—TEK—epithelium—breast cancer	0.000241	0.00386	CbGeAlD
Nilotinib—EPHA4—uterus—breast cancer	0.000238	0.00382	CbGeAlD
Nilotinib—FGR—endometrium—breast cancer	0.000237	0.0038	CbGeAlD
Nilotinib—CSF1R—embryo—breast cancer	0.000235	0.00378	CbGeAlD
Nilotinib—CA3—uterus—breast cancer	0.000235	0.00377	CbGeAlD
Nilotinib—BRAF—female gonad—breast cancer	0.000235	0.00377	CbGeAlD
Nilotinib—EPHA4—pituitary gland—breast cancer	0.000233	0.00375	CbGeAlD
Nilotinib—EPHB3—female gonad—breast cancer	0.000233	0.00374	CbGeAlD
Nilotinib—EPHA4—adipose tissue—breast cancer	0.000232	0.00373	CbGeAlD
Nilotinib—CA3—pituitary gland—breast cancer	0.000231	0.0037	CbGeAlD
Nilotinib—CA3—adipose tissue—breast cancer	0.00023	0.00369	CbGeAlD
Nilotinib—BLK—lymph node—breast cancer	0.00023	0.00369	CbGeAlD
Nilotinib—HCK—adrenal gland—breast cancer	0.000229	0.00368	CbGeAlD
Nilotinib—ABL2—adrenal gland—breast cancer	0.000228	0.00366	CbGeAlD
Nilotinib—EPHB4—endometrium—breast cancer	0.000225	0.00362	CbGeAlD
Nilotinib—ABL1—nipple—breast cancer	0.000225	0.00362	CbGeAlD
Nilotinib—HCK—bone marrow—breast cancer	0.000222	0.00356	CbGeAlD
Nilotinib—EPHA2—endometrium—breast cancer	0.000221	0.00355	CbGeAlD
Nilotinib—MAPK14—uterus—breast cancer	0.000219	0.00352	CbGeAlD
Nilotinib—ABL1—Epirubicin—Idarubicin—breast cancer	0.000219	0.132	CbGdCrCtD
Nilotinib—ABL1—Doxorubicin—Idarubicin—breast cancer	0.000219	0.132	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Idarubicin—breast cancer	0.000219	0.132	CbGdCrCtD
Nilotinib—EPHB6—skin of body—breast cancer	0.000219	0.00351	CbGeAlD
Nilotinib—LCK—uterus—breast cancer	0.000218	0.00351	CbGeAlD
Nilotinib—TEK—endometrium—breast cancer	0.000216	0.00346	CbGeAlD
Nilotinib—MAPK14—pituitary gland—breast cancer	0.000215	0.00346	CbGeAlD
Nilotinib—FGR—pituitary gland—breast cancer	0.000214	0.00344	CbGeAlD
Nilotinib—MAPK14—adipose tissue—breast cancer	0.000214	0.00344	CbGeAlD
Nilotinib—HCK—female gonad—breast cancer	0.000214	0.00344	CbGeAlD
Nilotinib—EPHA4—female reproductive system—breast cancer	0.000214	0.00343	CbGeAlD
Nilotinib—KIT—embryo—breast cancer	0.000214	0.00343	CbGeAlD
Nilotinib—FGR—adipose tissue—breast cancer	0.000213	0.00343	CbGeAlD
Nilotinib—LCK—adipose tissue—breast cancer	0.000213	0.00343	CbGeAlD
Nilotinib—ABL2—female gonad—breast cancer	0.000213	0.00341	CbGeAlD
Nilotinib—PDGFRB—embryo—breast cancer	0.000209	0.00335	CbGeAlD
Nilotinib—EPHA4—adrenal gland—breast cancer	0.000208	0.00335	CbGeAlD
Nilotinib—EPHB4—uterus—breast cancer	0.000208	0.00334	CbGeAlD
Nilotinib—EPHB6—endometrium—breast cancer	0.000206	0.00331	CbGeAlD
Nilotinib—EPHB4—pituitary gland—breast cancer	0.000204	0.00328	CbGeAlD
Nilotinib—EPHB4—adipose tissue—breast cancer	0.000203	0.00326	CbGeAlD
Nilotinib—MAPK11—lymph node—breast cancer	0.000202	0.00325	CbGeAlD
Nilotinib—CA9—female reproductive system—breast cancer	0.000202	0.00324	CbGeAlD
Nilotinib—Imatinib—ABL1—breast cancer	0.000201	0.0509	CrCbGaD
Nilotinib—CDC42BPB—lymph node—breast cancer	0.000201	0.00322	CbGeAlD
Nilotinib—EPHA2—pituitary gland—breast cancer	0.0002	0.00321	CbGeAlD
Nilotinib—EPHA2—adipose tissue—breast cancer	0.000199	0.0032	CbGeAlD
Nilotinib—CA3—bone marrow—breast cancer	0.000199	0.0032	CbGeAlD
Nilotinib—HCK—endocrine gland—breast cancer	0.000199	0.00319	CbGeAlD
Nilotinib—TEK—uterus—breast cancer	0.000199	0.00319	CbGeAlD
Nilotinib—MAPK14—female reproductive system—breast cancer	0.000197	0.00316	CbGeAlD
Nilotinib—FGR—female reproductive system—breast cancer	0.000196	0.00315	CbGeAlD
Nilotinib—TEK—pituitary gland—breast cancer	0.000195	0.00314	CbGeAlD
Nilotinib—TEK—adipose tissue—breast cancer	0.000194	0.00312	CbGeAlD
Nilotinib—EPHA4—female gonad—breast cancer	0.000194	0.00312	CbGeAlD
Nilotinib—MAPK14—adrenal gland—breast cancer	0.000192	0.00309	CbGeAlD
Nilotinib—LCK—adrenal gland—breast cancer	0.000191	0.00307	CbGeAlD
Nilotinib—FGR—adrenal gland—breast cancer	0.000191	0.00307	CbGeAlD
Nilotinib—EPHA3—lymph node—breast cancer	0.00019	0.00305	CbGeAlD
Nilotinib—CA14—adrenal gland—breast cancer	0.000187	0.003	CbGeAlD
Nilotinib—EPHB4—female reproductive system—breast cancer	0.000187	0.003	CbGeAlD
Nilotinib—EPHB6—pituitary gland—breast cancer	0.000187	0.003	CbGeAlD
Nilotinib—MAPK14—bone marrow—breast cancer	0.000186	0.00299	CbGeAlD
Nilotinib—ABL1—embryo—breast cancer	0.000186	0.00299	CbGeAlD
Nilotinib—EPHB6—adipose tissue—breast cancer	0.000186	0.00298	CbGeAlD
Nilotinib—FGR—bone marrow—breast cancer	0.000185	0.00297	CbGeAlD
Nilotinib—LCK—bone marrow—breast cancer	0.000185	0.00297	CbGeAlD
Nilotinib—CA4—nipple—breast cancer	0.000185	0.00297	CbGeAlD
Nilotinib—EPHA2—female reproductive system—breast cancer	0.000183	0.00294	CbGeAlD
Nilotinib—CSF1R—skin of body—breast cancer	0.000182	0.00293	CbGeAlD
Nilotinib—EPHB4—adrenal gland—breast cancer	0.000182	0.00293	CbGeAlD
Nilotinib—MAPK8—lymph node—breast cancer	0.000181	0.00291	CbGeAlD
Nilotinib—EPHA4—endocrine gland—breast cancer	0.000181	0.0029	CbGeAlD
Nilotinib—PDGFRA—uterus—breast cancer	0.00018	0.00289	CbGeAlD
Nilotinib—MAPK14—female gonad—breast cancer	0.000179	0.00288	CbGeAlD
Nilotinib—EPHA2—adrenal gland—breast cancer	0.000179	0.00287	CbGeAlD
Nilotinib—TEK—female reproductive system—breast cancer	0.000179	0.00287	CbGeAlD
Nilotinib—CA3—endocrine gland—breast cancer	0.000179	0.00287	CbGeAlD
Nilotinib—FGR—female gonad—breast cancer	0.000179	0.00287	CbGeAlD
Nilotinib—LCK—female gonad—breast cancer	0.000179	0.00287	CbGeAlD
Nilotinib—CYP2C8—mammary gland—breast cancer	0.000177	0.00284	CbGeAlD
Nilotinib—MAP2K5—endometrium—breast cancer	0.000176	0.00283	CbGeAlD
Nilotinib—EPHB4—bone marrow—breast cancer	0.000176	0.00283	CbGeAlD
Nilotinib—PDGFRA—adipose tissue—breast cancer	0.000176	0.00283	CbGeAlD
Nilotinib—TEK—adrenal gland—breast cancer	0.000174	0.0028	CbGeAlD
Nilotinib—KIT—epithelium—breast cancer	0.000174	0.0028	CbGeAlD
Nilotinib—CSF1R—endometrium—breast cancer	0.000172	0.00276	CbGeAlD
Nilotinib—CA9—endocrine gland—breast cancer	0.000171	0.00275	CbGeAlD
Nilotinib—PDGFRB—epithelium—breast cancer	0.00017	0.00273	CbGeAlD
Nilotinib—EPHB4—female gonad—breast cancer	0.00017	0.00273	CbGeAlD
Nilotinib—MAPK14—endocrine gland—breast cancer	0.000167	0.00268	CbGeAlD
Nilotinib—EPHA2—female gonad—breast cancer	0.000167	0.00268	CbGeAlD
Nilotinib—EPHB6—adrenal gland—breast cancer	0.000167	0.00268	CbGeAlD
Nilotinib—FGR—endocrine gland—breast cancer	0.000166	0.00267	CbGeAlD
Nilotinib—KIT—skin of body—breast cancer	0.000166	0.00266	CbGeAlD
Nilotinib—MAP4K1—lymph node—breast cancer	0.000165	0.00265	CbGeAlD
Nilotinib—TEK—female gonad—breast cancer	0.000163	0.00261	CbGeAlD
Nilotinib—PDGFRA—female reproductive system—breast cancer	0.000162	0.0026	CbGeAlD
Nilotinib—PDGFRB—skin of body—breast cancer	0.000162	0.0026	CbGeAlD
Nilotinib—Imatinib—KIT—breast cancer	0.000161	0.0409	CrCbGaD
Nilotinib—MAP2K5—pituitary gland—breast cancer	0.00016	0.00256	CbGeAlD
Nilotinib—MAP2K5—adipose tissue—breast cancer	0.000159	0.00255	CbGeAlD
Nilotinib—CSF1R—uterus—breast cancer	0.000159	0.00255	CbGeAlD
Nilotinib—EPHB4—endocrine gland—breast cancer	0.000158	0.00254	CbGeAlD
Nilotinib—PDGFRA—adrenal gland—breast cancer	0.000158	0.00254	CbGeAlD
Nilotinib—TIE1—lymph node—breast cancer	0.000157	0.00253	CbGeAlD
Nilotinib—CYP2C9—mammary gland—breast cancer	0.000157	0.00252	CbGeAlD
Nilotinib—KIT—endometrium—breast cancer	0.000156	0.00251	CbGeAlD
Nilotinib—CSF1R—pituitary gland—breast cancer	0.000156	0.0025	CbGeAlD
Nilotinib—EPHB6—female gonad—breast cancer	0.000155	0.0025	CbGeAlD
Nilotinib—CSF1R—adipose tissue—breast cancer	0.000155	0.00249	CbGeAlD
Nilotinib—EPHA2—endocrine gland—breast cancer	0.000155	0.00249	CbGeAlD
Nilotinib—Imatinib—CA9—breast cancer	0.000155	0.0392	CrCbGaD
Nilotinib—CA2—nipple—breast cancer	0.000153	0.00246	CbGeAlD
Nilotinib—PDGFRB—endometrium—breast cancer	0.000153	0.00245	CbGeAlD
Nilotinib—TEK—endocrine gland—breast cancer	0.000151	0.00243	CbGeAlD
Nilotinib—BRAF—lymph node—breast cancer	0.000151	0.00242	CbGeAlD
Nilotinib—EPHB3—lymph node—breast cancer	0.00015	0.0024	CbGeAlD
Nilotinib—CA12—female reproductive system—breast cancer	0.000149	0.0024	CbGeAlD
Nilotinib—PDGFRA—female gonad—breast cancer	0.000147	0.00237	CbGeAlD
Nilotinib—MAP2K5—female reproductive system—breast cancer	0.000146	0.00235	CbGeAlD
Nilotinib—Ponatinib—ABCG2—breast cancer	0.000145	0.0367	CrCbGaD
Nilotinib—ABL1—skin of body—breast cancer	0.000144	0.00232	CbGeAlD
Nilotinib—KIT—uterus—breast cancer	0.000144	0.00231	CbGeAlD
Nilotinib—CSF1R—female reproductive system—breast cancer	0.000143	0.00229	CbGeAlD
Nilotinib—MAP2K5—adrenal gland—breast cancer	0.000143	0.00229	CbGeAlD
Nilotinib—KIT—pituitary gland—breast cancer	0.000141	0.00227	CbGeAlD
Nilotinib—KIT—adipose tissue—breast cancer	0.000141	0.00226	CbGeAlD
Nilotinib—PDGFRB—uterus—breast cancer	0.000141	0.00226	CbGeAlD
Nilotinib—CSF1R—adrenal gland—breast cancer	0.000139	0.00223	CbGeAlD
Nilotinib—PDGFRB—pituitary gland—breast cancer	0.000138	0.00222	CbGeAlD
Nilotinib—PDGFRB—adipose tissue—breast cancer	0.000138	0.00221	CbGeAlD
Nilotinib—HCK—lymph node—breast cancer	0.000137	0.00221	CbGeAlD
Nilotinib—PDGFRA—endocrine gland—breast cancer	0.000137	0.0022	CbGeAlD
Nilotinib—ABL2—lymph node—breast cancer	0.000137	0.00219	CbGeAlD
Nilotinib—ABL1—endometrium—breast cancer	0.000136	0.00218	CbGeAlD
Nilotinib—CSF1R—bone marrow—breast cancer	0.000135	0.00216	CbGeAlD
Nilotinib—MAP2K5—female gonad—breast cancer	0.000133	0.00213	CbGeAlD
Nilotinib—UGT1A1—endocrine gland—breast cancer	0.000131	0.0021	CbGeAlD
Nilotinib—CSF1R—female gonad—breast cancer	0.00013	0.00208	CbGeAlD
Nilotinib—KIT—female reproductive system—breast cancer	0.000129	0.00208	CbGeAlD
Nilotinib—CA1—adipose tissue—breast cancer	0.000129	0.00207	CbGeAlD
Nilotinib—CA2—embryo—breast cancer	0.000127	0.00203	CbGeAlD
Nilotinib—CA12—endocrine gland—breast cancer	0.000126	0.00203	CbGeAlD
Nilotinib—PDGFRB—female reproductive system—breast cancer	0.000126	0.00203	CbGeAlD
Nilotinib—KIT—adrenal gland—breast cancer	0.000126	0.00203	CbGeAlD
Nilotinib—ABL1—uterus—breast cancer	0.000125	0.00201	CbGeAlD
Nilotinib—EPHA4—lymph node—breast cancer	0.000125	0.00201	CbGeAlD
Nilotinib—MAP2K5—endocrine gland—breast cancer	0.000124	0.00199	CbGeAlD
Nilotinib—CA3—lymph node—breast cancer	0.000123	0.00198	CbGeAlD
Nilotinib—PDGFRB—adrenal gland—breast cancer	0.000123	0.00198	CbGeAlD
Nilotinib—ABL1—pituitary gland—breast cancer	0.000123	0.00198	CbGeAlD
Nilotinib—ABL1—adipose tissue—breast cancer	0.000123	0.00197	CbGeAlD
Nilotinib—KIT—bone marrow—breast cancer	0.000122	0.00196	CbGeAlD
Nilotinib—CSF1R—endocrine gland—breast cancer	0.000121	0.00194	CbGeAlD
Nilotinib—PDGFRB—bone marrow—breast cancer	0.000119	0.00192	CbGeAlD
Nilotinib—CA1—female reproductive system—breast cancer	0.000118	0.0019	CbGeAlD
Nilotinib—KIT—female gonad—breast cancer	0.000118	0.00189	CbGeAlD
Nilotinib—MAPK14—lymph node—breast cancer	0.000115	0.00185	CbGeAlD
Nilotinib—PDGFRB—female gonad—breast cancer	0.000115	0.00185	CbGeAlD
Nilotinib—FGR—lymph node—breast cancer	0.000115	0.00184	CbGeAlD
Nilotinib—LCK—lymph node—breast cancer	0.000115	0.00184	CbGeAlD
Nilotinib—ABL1—female reproductive system—breast cancer	0.000113	0.00181	CbGeAlD
Nilotinib—CA1—bone marrow—breast cancer	0.000112	0.0018	CbGeAlD
Nilotinib—ABL1—adrenal gland—breast cancer	0.00011	0.00177	CbGeAlD
Nilotinib—KIT—endocrine gland—breast cancer	0.00011	0.00176	CbGeAlD
Nilotinib—EPHB4—lymph node—breast cancer	0.000109	0.00175	CbGeAlD
Nilotinib—EPHA2—lymph node—breast cancer	0.000107	0.00172	CbGeAlD
Nilotinib—PDGFRB—endocrine gland—breast cancer	0.000107	0.00172	CbGeAlD
Nilotinib—ABL1—bone marrow—breast cancer	0.000106	0.00171	CbGeAlD
Nilotinib—TEK—lymph node—breast cancer	0.000105	0.00168	CbGeAlD
Nilotinib—CA2—epithelium—breast cancer	0.000103	0.00166	CbGeAlD
Nilotinib—ABL1—female gonad—breast cancer	0.000103	0.00165	CbGeAlD
Nilotinib—CA4—pituitary gland—breast cancer	0.000101	0.00162	CbGeAlD
Nilotinib—CA4—adipose tissue—breast cancer	0.000101	0.00162	CbGeAlD
Nilotinib—ABL1—Idarubicin—Epirubicin—breast cancer	0.0001	0.0604	CbGdCrCtD
Nilotinib—ABL1—Doxorubicin—Epirubicin—breast cancer	0.0001	0.0604	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Epirubicin—breast cancer	0.0001	0.0604	CbGdCrCtD
Nilotinib—CA1—endocrine gland—breast cancer	0.0001	0.00161	CbGeAlD
Nilotinib—EPHB6—lymph node—breast cancer	9.99e-05	0.0016	CbGeAlD
Nilotinib—CA2—skin of body—breast cancer	9.82e-05	0.00158	CbGeAlD
Nilotinib—ABL1—endocrine gland—breast cancer	9.53e-05	0.00153	CbGeAlD
Nilotinib—PDGFRA—lymph node—breast cancer	9.47e-05	0.00152	CbGeAlD
Nilotinib—ABL1—Epirubicin—Doxorubicin—breast cancer	9.29e-05	0.0559	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Doxorubicin—breast cancer	9.29e-05	0.0559	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—breast cancer	9.29e-05	0.0559	CbGdCrCtD
Nilotinib—CA4—female reproductive system—breast cancer	9.25e-05	0.00149	CbGeAlD
Nilotinib—CA4—adrenal gland—breast cancer	9.03e-05	0.00145	CbGeAlD
Nilotinib—Imatinib—ABCG2—breast cancer	8.92e-05	0.0226	CrCbGaD
Nilotinib—CYP2C8—endometrium—breast cancer	8.82e-05	0.00142	CbGeAlD
Nilotinib—CA4—bone marrow—breast cancer	8.74e-05	0.0014	CbGeAlD
Nilotinib—ABCG2—endometrium—breast cancer	8.58e-05	0.00138	CbGeAlD
Nilotinib—MAP2K5—lymph node—breast cancer	8.54e-05	0.00137	CbGeAlD
Nilotinib—Ponatinib—CYP2D6—breast cancer	8.44e-05	0.0214	CrCbGaD
Nilotinib—CA4—female gonad—breast cancer	8.42e-05	0.00135	CbGeAlD
Nilotinib—CYP2B6—skin of body—breast cancer	8.39e-05	0.00135	CbGeAlD
Nilotinib—CA2—pituitary gland—breast cancer	8.38e-05	0.00135	CbGeAlD
Nilotinib—CA2—adipose tissue—breast cancer	8.35e-05	0.00134	CbGeAlD
Nilotinib—CSF1R—lymph node—breast cancer	8.34e-05	0.00134	CbGeAlD
Nilotinib—CYP2C8—pituitary gland—breast cancer	7.98e-05	0.00128	CbGeAlD
Nilotinib—ABCG2—uterus—breast cancer	7.9e-05	0.00127	CbGeAlD
Nilotinib—CA4—endocrine gland—breast cancer	7.83e-05	0.00126	CbGeAlD
Nilotinib—ABCG2—pituitary gland—breast cancer	7.76e-05	0.00125	CbGeAlD
Nilotinib—ABCG2—adipose tissue—breast cancer	7.73e-05	0.00124	CbGeAlD
Nilotinib—CA2—female reproductive system—breast cancer	7.67e-05	0.00123	CbGeAlD
Nilotinib—Imatinib—PTGS1—breast cancer	7.64e-05	0.0194	CrCbGaD
Nilotinib—KIT—lymph node—breast cancer	7.57e-05	0.00122	CbGeAlD
Nilotinib—CA2—adrenal gland—breast cancer	7.49e-05	0.0012	CbGeAlD
Nilotinib—PDGFRB—lymph node—breast cancer	7.39e-05	0.00119	CbGeAlD
Nilotinib—CYP2C8—female reproductive system—breast cancer	7.31e-05	0.00117	CbGeAlD
Nilotinib—Ponatinib—CYP3A4—breast cancer	7.24e-05	0.0184	CrCbGaD
Nilotinib—CA2—bone marrow—breast cancer	7.24e-05	0.00116	CbGeAlD
Nilotinib—CA2—female gonad—breast cancer	6.98e-05	0.00112	CbGeAlD
Nilotinib—ABCG2—adrenal gland—breast cancer	6.93e-05	0.00111	CbGeAlD
Nilotinib—CA1—lymph node—breast cancer	6.92e-05	0.00111	CbGeAlD
Nilotinib—ABCG2—bone marrow—breast cancer	6.71e-05	0.00108	CbGeAlD
Nilotinib—ABL1—lymph node—breast cancer	6.59e-05	0.00106	CbGeAlD
Nilotinib—CYP2B6—female reproductive system—breast cancer	6.55e-05	0.00105	CbGeAlD
Nilotinib—CA2—endocrine gland—breast cancer	6.49e-05	0.00104	CbGeAlD
Nilotinib—CYP2C9—female reproductive system—breast cancer	6.49e-05	0.00104	CbGeAlD
Nilotinib—ABCG2—female gonad—breast cancer	6.47e-05	0.00104	CbGeAlD
Nilotinib—CYP2B6—adrenal gland—breast cancer	6.4e-05	0.00103	CbGeAlD
Nilotinib—CYP2C8—endocrine gland—breast cancer	6.18e-05	0.000993	CbGeAlD
Nilotinib—Ponatinib—ABCB1—breast cancer	6.03e-05	0.0153	CrCbGaD
Nilotinib—ABCB1—embryo—breast cancer	5.78e-05	0.000928	CbGeAlD
Nilotinib—CYP2B6—endocrine gland—breast cancer	5.55e-05	0.000891	CbGeAlD
Nilotinib—CYP2C9—endocrine gland—breast cancer	5.49e-05	0.000882	CbGeAlD
Nilotinib—CA4—lymph node—breast cancer	5.41e-05	0.000869	CbGeAlD
Nilotinib—Imatinib—CYP2D6—breast cancer	5.2e-05	0.0132	CrCbGaD
Nilotinib—CYP3A4—female reproductive system—breast cancer	4.95e-05	0.000795	CbGeAlD
Nilotinib—CYP2D6—female reproductive system—breast cancer	4.87e-05	0.000782	CbGeAlD
Nilotinib—ABCB1—epithelium—breast cancer	4.72e-05	0.000758	CbGeAlD
Nilotinib—CA2—lymph node—breast cancer	4.49e-05	0.000721	CbGeAlD
Nilotinib—Imatinib—CYP3A4—breast cancer	4.46e-05	0.0113	CrCbGaD
Nilotinib—CYP2D6—female gonad—breast cancer	4.43e-05	0.000712	CbGeAlD
Nilotinib—ABCB1—endometrium—breast cancer	4.23e-05	0.000679	CbGeAlD
Nilotinib—CYP3A4—endocrine gland—breast cancer	4.19e-05	0.000673	CbGeAlD
Nilotinib—ABCG2—lymph node—breast cancer	4.16e-05	0.000668	CbGeAlD
Nilotinib—CYP2D6—endocrine gland—breast cancer	4.12e-05	0.000662	CbGeAlD
Nilotinib—ABCB1—uterus—breast cancer	3.9e-05	0.000626	CbGeAlD
Nilotinib—Imatinib—ALB—breast cancer	3.89e-05	0.00986	CrCbGaD
Nilotinib—ABCB1—pituitary gland—breast cancer	3.83e-05	0.000615	CbGeAlD
Nilotinib—ABCB1—adipose tissue—breast cancer	3.81e-05	0.000612	CbGeAlD
Nilotinib—Imatinib—ABCB1—breast cancer	3.71e-05	0.00941	CrCbGaD
Nilotinib—ABCB1—female reproductive system—breast cancer	3.5e-05	0.000563	CbGeAlD
Nilotinib—ABCB1—adrenal gland—breast cancer	3.42e-05	0.000549	CbGeAlD
Nilotinib—ABCB1—bone marrow—breast cancer	3.31e-05	0.000531	CbGeAlD
Nilotinib—ABCB1—female gonad—breast cancer	3.19e-05	0.000512	CbGeAlD
Nilotinib—ABCB1—endocrine gland—breast cancer	2.96e-05	0.000476	CbGeAlD
Nilotinib—ABCB1—lymph node—breast cancer	2.05e-05	0.000329	CbGeAlD
Nilotinib—Rash—Fluorouracil—breast cancer	1.32e-05	0.000104	CcSEcCtD
Nilotinib—Dermatitis—Fluorouracil—breast cancer	1.32e-05	0.000104	CcSEcCtD
Nilotinib—Pharyngitis—Doxorubicin—breast cancer	1.32e-05	0.000103	CcSEcCtD
Nilotinib—Paraesthesia—Capecitabine—breast cancer	1.31e-05	0.000103	CcSEcCtD
Nilotinib—Decreased appetite—Docetaxel—breast cancer	1.31e-05	0.000103	CcSEcCtD
Nilotinib—Hypersensitivity—Paclitaxel—breast cancer	1.31e-05	0.000103	CcSEcCtD
Nilotinib—Headache—Fluorouracil—breast cancer	1.31e-05	0.000103	CcSEcCtD
Nilotinib—Urinary tract disorder—Doxorubicin—breast cancer	1.31e-05	0.000103	CcSEcCtD
Nilotinib—Oedema peripheral—Doxorubicin—breast cancer	1.31e-05	0.000103	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—breast cancer	1.31e-05	0.000103	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Docetaxel—breast cancer	1.3e-05	0.000102	CcSEcCtD
Nilotinib—Connective tissue disorder—Doxorubicin—breast cancer	1.3e-05	0.000102	CcSEcCtD
Nilotinib—Dyspnoea—Capecitabine—breast cancer	1.3e-05	0.000102	CcSEcCtD
Nilotinib—Fatigue—Docetaxel—breast cancer	1.3e-05	0.000102	CcSEcCtD
Nilotinib—Angiopathy—Epirubicin—breast cancer	1.3e-05	0.000102	CcSEcCtD
Nilotinib—Urethral disorder—Doxorubicin—breast cancer	1.3e-05	0.000102	CcSEcCtD
Nilotinib—Nausea—Irinotecan—breast cancer	1.3e-05	0.000102	CcSEcCtD
Nilotinib—Nausea—Mitoxantrone—breast cancer	1.3e-05	0.000102	CcSEcCtD
Nilotinib—Immune system disorder—Epirubicin—breast cancer	1.3e-05	0.000102	CcSEcCtD
Nilotinib—Mediastinal disorder—Epirubicin—breast cancer	1.29e-05	0.000102	CcSEcCtD
Nilotinib—Pain—Docetaxel—breast cancer	1.29e-05	0.000101	CcSEcCtD
Nilotinib—Constipation—Docetaxel—breast cancer	1.29e-05	0.000101	CcSEcCtD
Nilotinib—Back pain—Methotrexate—breast cancer	1.29e-05	0.000101	CcSEcCtD
Nilotinib—Dyspepsia—Capecitabine—breast cancer	1.29e-05	0.000101	CcSEcCtD
Nilotinib—Chills—Epirubicin—breast cancer	1.29e-05	0.000101	CcSEcCtD
Nilotinib—Arrhythmia—Epirubicin—breast cancer	1.28e-05	0.000101	CcSEcCtD
Nilotinib—Visual impairment—Doxorubicin—breast cancer	1.28e-05	0.0001	CcSEcCtD
Nilotinib—Asthenia—Paclitaxel—breast cancer	1.28e-05	0.0001	CcSEcCtD
Nilotinib—Decreased appetite—Capecitabine—breast cancer	1.27e-05	9.99e-05	CcSEcCtD
Nilotinib—Alopecia—Epirubicin—breast cancer	1.27e-05	9.95e-05	CcSEcCtD
Nilotinib—Nausea—Gemcitabine—breast cancer	1.27e-05	9.93e-05	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Capecitabine—breast cancer	1.26e-05	9.92e-05	CcSEcCtD
Nilotinib—Fatigue—Capecitabine—breast cancer	1.26e-05	9.9e-05	CcSEcCtD
Nilotinib—Pruritus—Paclitaxel—breast cancer	1.26e-05	9.9e-05	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—breast cancer	1.26e-05	9.87e-05	CcSEcCtD
Nilotinib—Mental disorder—Epirubicin—breast cancer	1.26e-05	9.87e-05	CcSEcCtD
Nilotinib—Erythema multiforme—Doxorubicin—breast cancer	1.26e-05	9.85e-05	CcSEcCtD
Nilotinib—Pain—Capecitabine—breast cancer	1.25e-05	9.82e-05	CcSEcCtD
Nilotinib—Constipation—Capecitabine—breast cancer	1.25e-05	9.82e-05	CcSEcCtD
Nilotinib—Malnutrition—Epirubicin—breast cancer	1.25e-05	9.81e-05	CcSEcCtD
Nilotinib—Erythema—Epirubicin—breast cancer	1.25e-05	9.81e-05	CcSEcCtD
Nilotinib—Feeling abnormal—Docetaxel—breast cancer	1.25e-05	9.78e-05	CcSEcCtD
Nilotinib—Nausea—Fluorouracil—breast cancer	1.24e-05	9.76e-05	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—breast cancer	1.24e-05	9.74e-05	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—breast cancer	1.24e-05	9.72e-05	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—breast cancer	1.24e-05	9.72e-05	CcSEcCtD
Nilotinib—Gastrointestinal pain—Docetaxel—breast cancer	1.24e-05	9.7e-05	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—breast cancer	1.23e-05	9.68e-05	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—breast cancer	1.23e-05	9.67e-05	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—breast cancer	1.23e-05	9.67e-05	CcSEcCtD
Nilotinib—Flatulence—Epirubicin—breast cancer	1.23e-05	9.66e-05	CcSEcCtD
Nilotinib—Dysgeusia—Epirubicin—breast cancer	1.22e-05	9.6e-05	CcSEcCtD
Nilotinib—Diarrhoea—Paclitaxel—breast cancer	1.22e-05	9.58e-05	CcSEcCtD
Nilotinib—Back pain—Epirubicin—breast cancer	1.21e-05	9.48e-05	CcSEcCtD
Nilotinib—Feeling abnormal—Capecitabine—breast cancer	1.21e-05	9.47e-05	CcSEcCtD
Nilotinib—Angiopathy—Doxorubicin—breast cancer	1.2e-05	9.46e-05	CcSEcCtD
Nilotinib—Malaise—Methotrexate—breast cancer	1.2e-05	9.45e-05	CcSEcCtD
Nilotinib—Muscle spasms—Epirubicin—breast cancer	1.2e-05	9.43e-05	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—breast cancer	1.2e-05	9.41e-05	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—breast cancer	1.2e-05	9.41e-05	CcSEcCtD
Nilotinib—Gastrointestinal pain—Capecitabine—breast cancer	1.2e-05	9.39e-05	CcSEcCtD
Nilotinib—Mediastinal disorder—Doxorubicin—breast cancer	1.2e-05	9.39e-05	CcSEcCtD
Nilotinib—Body temperature increased—Docetaxel—breast cancer	1.19e-05	9.38e-05	CcSEcCtD
Nilotinib—Abdominal pain—Docetaxel—breast cancer	1.19e-05	9.38e-05	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—breast cancer	1.19e-05	9.38e-05	CcSEcCtD
Nilotinib—Chills—Doxorubicin—breast cancer	1.19e-05	9.35e-05	CcSEcCtD
Nilotinib—Arrhythmia—Doxorubicin—breast cancer	1.19e-05	9.31e-05	CcSEcCtD
Nilotinib—Dizziness—Paclitaxel—breast cancer	1.18e-05	9.26e-05	CcSEcCtD
Nilotinib—Vision blurred—Epirubicin—breast cancer	1.18e-05	9.24e-05	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—breast cancer	1.17e-05	9.21e-05	CcSEcCtD
Nilotinib—Cough—Methotrexate—breast cancer	1.16e-05	9.14e-05	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—breast cancer	1.16e-05	9.13e-05	CcSEcCtD
Nilotinib—Urticaria—Capecitabine—breast cancer	1.16e-05	9.13e-05	CcSEcCtD
Nilotinib—Ill-defined disorder—Epirubicin—breast cancer	1.16e-05	9.1e-05	CcSEcCtD
Nilotinib—Body temperature increased—Capecitabine—breast cancer	1.16e-05	9.08e-05	CcSEcCtD
Nilotinib—Abdominal pain—Capecitabine—breast cancer	1.16e-05	9.08e-05	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—breast cancer	1.16e-05	9.07e-05	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—breast cancer	1.16e-05	9.07e-05	CcSEcCtD
Nilotinib—Anaemia—Epirubicin—breast cancer	1.15e-05	9.06e-05	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—breast cancer	1.14e-05	8.94e-05	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—breast cancer	1.14e-05	8.92e-05	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—breast cancer	1.14e-05	8.92e-05	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—breast cancer	1.14e-05	8.92e-05	CcSEcCtD
Nilotinib—Vomiting—Paclitaxel—breast cancer	1.13e-05	8.9e-05	CcSEcCtD
Nilotinib—Dysgeusia—Doxorubicin—breast cancer	1.13e-05	8.88e-05	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.13e-05	8.86e-05	CcSEcCtD
Nilotinib—Malaise—Epirubicin—breast cancer	1.13e-05	8.84e-05	CcSEcCtD
Nilotinib—Rash—Paclitaxel—breast cancer	1.12e-05	8.83e-05	CcSEcCtD
Nilotinib—Dermatitis—Paclitaxel—breast cancer	1.12e-05	8.82e-05	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—breast cancer	1.12e-05	8.81e-05	CcSEcCtD
Nilotinib—Vertigo—Epirubicin—breast cancer	1.12e-05	8.81e-05	CcSEcCtD
Nilotinib—Syncope—Epirubicin—breast cancer	1.12e-05	8.79e-05	CcSEcCtD
Nilotinib—Leukopenia—Epirubicin—breast cancer	1.12e-05	8.78e-05	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—breast cancer	1.12e-05	8.78e-05	CcSEcCtD
Nilotinib—Headache—Paclitaxel—breast cancer	1.12e-05	8.77e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Docetaxel—breast cancer	1.11e-05	8.74e-05	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—breast cancer	1.11e-05	8.72e-05	CcSEcCtD
Nilotinib—Palpitations—Epirubicin—breast cancer	1.1e-05	8.66e-05	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—breast cancer	1.1e-05	8.62e-05	CcSEcCtD
Nilotinib—Loss of consciousness—Epirubicin—breast cancer	1.1e-05	8.62e-05	CcSEcCtD
Nilotinib—Cough—Epirubicin—breast cancer	1.09e-05	8.56e-05	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—breast cancer	1.09e-05	8.55e-05	CcSEcCtD
Nilotinib—Asthenia—Docetaxel—breast cancer	1.08e-05	8.51e-05	CcSEcCtD
Nilotinib—Infection—Methotrexate—breast cancer	1.08e-05	8.5e-05	CcSEcCtD
Nilotinib—Hypertension—Epirubicin—breast cancer	1.08e-05	8.47e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Capecitabine—breast cancer	1.08e-05	8.46e-05	CcSEcCtD
Nilotinib—Ill-defined disorder—Doxorubicin—breast cancer	1.07e-05	8.42e-05	CcSEcCtD
Nilotinib—Pruritus—Docetaxel—breast cancer	1.07e-05	8.39e-05	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—breast cancer	1.07e-05	8.39e-05	CcSEcCtD
Nilotinib—Anaemia—Doxorubicin—breast cancer	1.07e-05	8.39e-05	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—breast cancer	1.07e-05	8.37e-05	CcSEcCtD
Nilotinib—Arthralgia—Epirubicin—breast cancer	1.06e-05	8.35e-05	CcSEcCtD
Nilotinib—Myalgia—Epirubicin—breast cancer	1.06e-05	8.35e-05	CcSEcCtD
Nilotinib—Chest pain—Epirubicin—breast cancer	1.06e-05	8.35e-05	CcSEcCtD
Nilotinib—Anxiety—Epirubicin—breast cancer	1.06e-05	8.32e-05	CcSEcCtD
Nilotinib—Nausea—Paclitaxel—breast cancer	1.06e-05	8.31e-05	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—breast cancer	1.06e-05	8.31e-05	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.06e-05	8.29e-05	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—breast cancer	1.05e-05	8.27e-05	CcSEcCtD
Nilotinib—Discomfort—Epirubicin—breast cancer	1.05e-05	8.25e-05	CcSEcCtD
Nilotinib—Asthenia—Capecitabine—breast cancer	1.05e-05	8.24e-05	CcSEcCtD
Nilotinib—Malaise—Doxorubicin—breast cancer	1.04e-05	8.18e-05	CcSEcCtD
Nilotinib—Dry mouth—Epirubicin—breast cancer	1.04e-05	8.16e-05	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—breast cancer	1.04e-05	8.15e-05	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—breast cancer	1.04e-05	8.15e-05	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—breast cancer	1.04e-05	8.14e-05	CcSEcCtD
Nilotinib—Pruritus—Capecitabine—breast cancer	1.04e-05	8.13e-05	CcSEcCtD
Nilotinib—Leukopenia—Doxorubicin—breast cancer	1.03e-05	8.12e-05	CcSEcCtD
Nilotinib—Diarrhoea—Docetaxel—breast cancer	1.03e-05	8.12e-05	CcSEcCtD
Nilotinib—Confusional state—Epirubicin—breast cancer	1.03e-05	8.07e-05	CcSEcCtD
Nilotinib—Palpitations—Doxorubicin—breast cancer	1.02e-05	8.02e-05	CcSEcCtD
Nilotinib—Oedema—Epirubicin—breast cancer	1.02e-05	8e-05	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—breast cancer	1.02e-05	7.99e-05	CcSEcCtD
Nilotinib—Loss of consciousness—Doxorubicin—breast cancer	1.02e-05	7.97e-05	CcSEcCtD
Nilotinib—Infection—Epirubicin—breast cancer	1.01e-05	7.95e-05	CcSEcCtD
Nilotinib—Cough—Doxorubicin—breast cancer	1.01e-05	7.92e-05	CcSEcCtD
Nilotinib—Shock—Epirubicin—breast cancer	1e-05	7.87e-05	CcSEcCtD
Nilotinib—Diarrhoea—Capecitabine—breast cancer	1e-05	7.86e-05	CcSEcCtD
Nilotinib—Nervous system disorder—Epirubicin—breast cancer	1e-05	7.85e-05	CcSEcCtD
Nilotinib—Dizziness—Docetaxel—breast cancer	9.99e-06	7.85e-05	CcSEcCtD
Nilotinib—Thrombocytopenia—Epirubicin—breast cancer	9.98e-06	7.84e-05	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—breast cancer	9.98e-06	7.83e-05	CcSEcCtD
Nilotinib—Tachycardia—Epirubicin—breast cancer	9.95e-06	7.81e-05	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—breast cancer	9.92e-06	7.79e-05	CcSEcCtD
Nilotinib—Skin disorder—Epirubicin—breast cancer	9.9e-06	7.77e-05	CcSEcCtD
Nilotinib—Hyperhidrosis—Epirubicin—breast cancer	9.85e-06	7.74e-05	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—breast cancer	9.85e-06	7.73e-05	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—breast cancer	9.84e-06	7.72e-05	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—breast cancer	9.84e-06	7.72e-05	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—breast cancer	9.84e-06	7.72e-05	CcSEcCtD
Nilotinib—Anxiety—Doxorubicin—breast cancer	9.81e-06	7.7e-05	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—breast cancer	9.78e-06	7.68e-05	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	9.77e-06	7.67e-05	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—breast cancer	9.72e-06	7.63e-05	CcSEcCtD
Nilotinib—Anorexia—Epirubicin—breast cancer	9.72e-06	7.63e-05	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—breast cancer	9.71e-06	7.62e-05	CcSEcCtD
Nilotinib—Dizziness—Capecitabine—breast cancer	9.68e-06	7.6e-05	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—breast cancer	9.62e-06	7.55e-05	CcSEcCtD
Nilotinib—Vomiting—Docetaxel—breast cancer	9.61e-06	7.54e-05	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—breast cancer	9.59e-06	7.53e-05	CcSEcCtD
Nilotinib—Rash—Docetaxel—breast cancer	9.53e-06	7.48e-05	CcSEcCtD
Nilotinib—Hypotension—Epirubicin—breast cancer	9.53e-06	7.48e-05	CcSEcCtD
Nilotinib—Dermatitis—Docetaxel—breast cancer	9.52e-06	7.47e-05	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—breast cancer	9.51e-06	7.47e-05	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—breast cancer	9.47e-06	7.43e-05	CcSEcCtD
Nilotinib—Headache—Docetaxel—breast cancer	9.47e-06	7.43e-05	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—breast cancer	9.43e-06	7.4e-05	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—breast cancer	9.4e-06	7.38e-05	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—breast cancer	9.39e-06	7.37e-05	CcSEcCtD
Nilotinib—Infection—Doxorubicin—breast cancer	9.37e-06	7.36e-05	CcSEcCtD
Nilotinib—Pain—Methotrexate—breast cancer	9.32e-06	7.31e-05	CcSEcCtD
Nilotinib—Vomiting—Capecitabine—breast cancer	9.3e-06	7.3e-05	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Epirubicin—breast cancer	9.29e-06	7.29e-05	CcSEcCtD
Nilotinib—Shock—Doxorubicin—breast cancer	9.28e-06	7.28e-05	CcSEcCtD
Nilotinib—Nervous system disorder—Doxorubicin—breast cancer	9.25e-06	7.26e-05	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—breast cancer	9.24e-06	7.25e-05	CcSEcCtD
Nilotinib—Rash—Capecitabine—breast cancer	9.23e-06	7.24e-05	CcSEcCtD
Nilotinib—Insomnia—Epirubicin—breast cancer	9.22e-06	7.24e-05	CcSEcCtD
Nilotinib—Dermatitis—Capecitabine—breast cancer	9.22e-06	7.24e-05	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—breast cancer	9.21e-06	7.23e-05	CcSEcCtD
Nilotinib—Headache—Capecitabine—breast cancer	9.17e-06	7.2e-05	CcSEcCtD
Nilotinib—Skin disorder—Doxorubicin—breast cancer	9.16e-06	7.19e-05	CcSEcCtD
Nilotinib—Paraesthesia—Epirubicin—breast cancer	9.15e-06	7.19e-05	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—breast cancer	9.12e-06	7.16e-05	CcSEcCtD
Nilotinib—Dyspnoea—Epirubicin—breast cancer	9.09e-06	7.13e-05	CcSEcCtD
Nilotinib—Anorexia—Doxorubicin—breast cancer	8.99e-06	7.06e-05	CcSEcCtD
Nilotinib—Nausea—Docetaxel—breast cancer	8.98e-06	7.05e-05	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—breast cancer	8.98e-06	7.05e-05	CcSEcCtD
Nilotinib—Dyspepsia—Epirubicin—breast cancer	8.97e-06	7.04e-05	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—breast cancer	8.91e-06	6.99e-05	CcSEcCtD
Nilotinib—Decreased appetite—Epirubicin—breast cancer	8.86e-06	6.96e-05	CcSEcCtD
Nilotinib—Hypotension—Doxorubicin—breast cancer	8.81e-06	6.92e-05	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Epirubicin—breast cancer	8.8e-06	6.91e-05	CcSEcCtD
Nilotinib—Fatigue—Epirubicin—breast cancer	8.79e-06	6.9e-05	CcSEcCtD
Nilotinib—Constipation—Epirubicin—breast cancer	8.72e-06	6.84e-05	CcSEcCtD
Nilotinib—Pain—Epirubicin—breast cancer	8.72e-06	6.84e-05	CcSEcCtD
Nilotinib—Nausea—Capecitabine—breast cancer	8.69e-06	6.82e-05	CcSEcCtD
Nilotinib—Urticaria—Methotrexate—breast cancer	8.65e-06	6.79e-05	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—breast cancer	8.61e-06	6.76e-05	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—breast cancer	8.61e-06	6.76e-05	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—breast cancer	8.59e-06	6.75e-05	CcSEcCtD
Nilotinib—Insomnia—Doxorubicin—breast cancer	8.53e-06	6.7e-05	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—breast cancer	8.47e-06	6.65e-05	CcSEcCtD
Nilotinib—Dyspnoea—Doxorubicin—breast cancer	8.41e-06	6.6e-05	CcSEcCtD
Nilotinib—Feeling abnormal—Epirubicin—breast cancer	8.4e-06	6.59e-05	CcSEcCtD
Nilotinib—Gastrointestinal pain—Epirubicin—breast cancer	8.34e-06	6.54e-05	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—breast cancer	8.3e-06	6.52e-05	CcSEcCtD
Nilotinib—Decreased appetite—Doxorubicin—breast cancer	8.2e-06	6.44e-05	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Doxorubicin—breast cancer	8.14e-06	6.39e-05	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—breast cancer	8.13e-06	6.38e-05	CcSEcCtD
Nilotinib—Urticaria—Epirubicin—breast cancer	8.1e-06	6.36e-05	CcSEcCtD
Nilotinib—Constipation—Doxorubicin—breast cancer	8.07e-06	6.33e-05	CcSEcCtD
Nilotinib—Pain—Doxorubicin—breast cancer	8.07e-06	6.33e-05	CcSEcCtD
Nilotinib—Abdominal pain—Epirubicin—breast cancer	8.06e-06	6.33e-05	CcSEcCtD
Nilotinib—Body temperature increased—Epirubicin—breast cancer	8.06e-06	6.33e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—breast cancer	8.03e-06	6.3e-05	CcSEcCtD
Nilotinib—Asthenia—Methotrexate—breast cancer	7.82e-06	6.14e-05	CcSEcCtD
Nilotinib—Feeling abnormal—Doxorubicin—breast cancer	7.77e-06	6.1e-05	CcSEcCtD
Nilotinib—Gastrointestinal pain—Doxorubicin—breast cancer	7.71e-06	6.05e-05	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—breast cancer	7.71e-06	6.05e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Epirubicin—breast cancer	7.51e-06	5.9e-05	CcSEcCtD
Nilotinib—Urticaria—Doxorubicin—breast cancer	7.49e-06	5.88e-05	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—breast cancer	7.46e-06	5.85e-05	CcSEcCtD
Nilotinib—Abdominal pain—Doxorubicin—breast cancer	7.46e-06	5.85e-05	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—breast cancer	7.45e-06	5.85e-05	CcSEcCtD
Nilotinib—Asthenia—Epirubicin—breast cancer	7.31e-06	5.74e-05	CcSEcCtD
Nilotinib—Pruritus—Epirubicin—breast cancer	7.21e-06	5.66e-05	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—breast cancer	7.2e-06	5.65e-05	CcSEcCtD
Nilotinib—Diarrhoea—Epirubicin—breast cancer	6.97e-06	5.48e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Doxorubicin—breast cancer	6.95e-06	5.46e-05	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—breast cancer	6.93e-06	5.44e-05	CcSEcCtD
Nilotinib—Rash—Methotrexate—breast cancer	6.87e-06	5.39e-05	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—breast cancer	6.86e-06	5.39e-05	CcSEcCtD
Nilotinib—Headache—Methotrexate—breast cancer	6.82e-06	5.36e-05	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—breast cancer	6.77e-06	5.31e-05	CcSEcCtD
Nilotinib—Dizziness—Epirubicin—breast cancer	6.74e-06	5.29e-05	CcSEcCtD
Nilotinib—Pruritus—Doxorubicin—breast cancer	6.67e-06	5.24e-05	CcSEcCtD
Nilotinib—Vomiting—Epirubicin—breast cancer	6.48e-06	5.09e-05	CcSEcCtD
Nilotinib—Nausea—Methotrexate—breast cancer	6.47e-06	5.08e-05	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—breast cancer	6.45e-06	5.07e-05	CcSEcCtD
Nilotinib—Rash—Epirubicin—breast cancer	6.43e-06	5.05e-05	CcSEcCtD
Nilotinib—Dermatitis—Epirubicin—breast cancer	6.42e-06	5.04e-05	CcSEcCtD
Nilotinib—Headache—Epirubicin—breast cancer	6.39e-06	5.01e-05	CcSEcCtD
Nilotinib—Dizziness—Doxorubicin—breast cancer	6.24e-06	4.9e-05	CcSEcCtD
Nilotinib—Nausea—Epirubicin—breast cancer	6.06e-06	4.75e-05	CcSEcCtD
Nilotinib—Vomiting—Doxorubicin—breast cancer	6e-06	4.71e-05	CcSEcCtD
Nilotinib—Rash—Doxorubicin—breast cancer	5.95e-06	4.67e-05	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—breast cancer	5.94e-06	4.66e-05	CcSEcCtD
Nilotinib—Headache—Doxorubicin—breast cancer	5.91e-06	4.64e-05	CcSEcCtD
Nilotinib—Nausea—Doxorubicin—breast cancer	5.6e-06	4.4e-05	CcSEcCtD
Nilotinib—PDGFRB—Signaling Pathways—MAPK8—breast cancer	2.92e-07	2.21e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TYMS—breast cancer	2.91e-07	2.2e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—breast cancer	2.91e-07	2.2e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—breast cancer	2.91e-07	2.19e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—breast cancer	2.9e-07	2.19e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP1A1—breast cancer	2.9e-07	2.19e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TYMS—breast cancer	2.89e-07	2.18e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—breast cancer	2.89e-07	2.18e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—breast cancer	2.89e-07	2.18e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTM1—breast cancer	2.88e-07	2.17e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PLA2G4A—breast cancer	2.88e-07	2.17e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NCOR1—breast cancer	2.88e-07	2.17e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—breast cancer	2.87e-07	2.17e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ERCC2—breast cancer	2.87e-07	2.17e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—JUN—breast cancer	2.87e-07	2.16e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK8—breast cancer	2.86e-07	2.16e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CAV1—breast cancer	2.86e-07	2.16e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PLA2G4A—breast cancer	2.86e-07	2.15e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NCOR1—breast cancer	2.86e-07	2.15e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTM1—breast cancer	2.86e-07	2.15e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MDM2—breast cancer	2.85e-07	2.15e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—breast cancer	2.85e-07	2.15e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—breast cancer	2.85e-07	2.15e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—breast cancer	2.85e-07	2.15e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CTNNB1—breast cancer	2.85e-07	2.15e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RAF1—breast cancer	2.84e-07	2.15e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—breast cancer	2.84e-07	2.14e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK3—breast cancer	2.84e-07	2.14e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RELA—breast cancer	2.83e-07	2.14e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—breast cancer	2.83e-07	2.13e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—breast cancer	2.81e-07	2.12e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB2—breast cancer	2.81e-07	2.12e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—breast cancer	2.81e-07	2.12e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—breast cancer	2.8e-07	2.11e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP17A1—breast cancer	2.8e-07	2.11e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—breast cancer	2.79e-07	2.11e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—breast cancer	2.79e-07	2.1e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—breast cancer	2.78e-07	2.1e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1A—breast cancer	2.78e-07	2.1e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTEN—breast cancer	2.78e-07	2.1e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MTOR—breast cancer	2.78e-07	2.09e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CB—breast cancer	2.78e-07	2.09e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTEN—breast cancer	2.77e-07	2.09e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SRC—breast cancer	2.77e-07	2.09e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ENO1—breast cancer	2.77e-07	2.09e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS1—breast cancer	2.77e-07	2.09e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GPX1—breast cancer	2.76e-07	2.08e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—breast cancer	2.76e-07	2.08e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—breast cancer	2.75e-07	2.08e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—breast cancer	2.74e-07	2.07e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GPX1—breast cancer	2.73e-07	2.06e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.73e-07	2.06e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—breast cancer	2.73e-07	2.06e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP1A1—breast cancer	2.73e-07	2.06e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—breast cancer	2.72e-07	2.05e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2D6—breast cancer	2.72e-07	2.05e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK8—breast cancer	2.71e-07	2.05e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SRC—breast cancer	2.71e-07	2.05e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ERCC2—breast cancer	2.71e-07	2.04e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP1A1—breast cancer	2.71e-07	2.04e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CD—breast cancer	2.71e-07	2.04e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—MTHFR—breast cancer	2.7e-07	2.04e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—breast cancer	2.7e-07	2.04e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—breast cancer	2.7e-07	2.04e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—breast cancer	2.69e-07	2.03e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ERCC2—breast cancer	2.68e-07	2.03e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—breast cancer	2.68e-07	2.02e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—breast cancer	2.67e-07	2.02e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—breast cancer	2.67e-07	2.02e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—breast cancer	2.67e-07	2.01e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—breast cancer	2.67e-07	2.01e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—breast cancer	2.67e-07	2.01e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NCOA2—breast cancer	2.67e-07	2.01e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—breast cancer	2.66e-07	2.01e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—breast cancer	2.65e-07	2e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—breast cancer	2.64e-07	1.99e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—breast cancer	2.63e-07	1.98e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—breast cancer	2.63e-07	1.98e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—breast cancer	2.62e-07	1.98e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—breast cancer	2.62e-07	1.97e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—breast cancer	2.61e-07	1.97e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1B—breast cancer	2.61e-07	1.97e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CG—breast cancer	2.61e-07	1.97e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—breast cancer	2.6e-07	1.96e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—FASN—breast cancer	2.59e-07	1.95e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—BCHE—breast cancer	2.58e-07	1.94e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SRC—breast cancer	2.57e-07	1.94e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—NOS3—breast cancer	2.55e-07	1.93e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK3—breast cancer	2.55e-07	1.93e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—breast cancer	2.55e-07	1.93e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—breast cancer	2.55e-07	1.92e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—breast cancer	2.55e-07	1.92e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—MTHFR—breast cancer	2.55e-07	1.92e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC5A5—breast cancer	2.54e-07	1.92e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—breast cancer	2.54e-07	1.91e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—MTHFR—breast cancer	2.52e-07	1.9e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—breast cancer	2.51e-07	1.9e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—breast cancer	2.51e-07	1.89e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK3—breast cancer	2.5e-07	1.89e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CAV1—breast cancer	2.49e-07	1.88e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—breast cancer	2.49e-07	1.88e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—breast cancer	2.48e-07	1.87e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—breast cancer	2.48e-07	1.87e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JUN—breast cancer	2.48e-07	1.87e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—breast cancer	2.48e-07	1.87e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—breast cancer	2.47e-07	1.87e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—breast cancer	2.47e-07	1.87e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CTNNB1—breast cancer	2.46e-07	1.86e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—breast cancer	2.46e-07	1.86e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—breast cancer	2.46e-07	1.86e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NQO1—breast cancer	2.46e-07	1.85e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC2A1—breast cancer	2.46e-07	1.85e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—breast cancer	2.43e-07	1.84e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—breast cancer	2.43e-07	1.83e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—breast cancer	2.43e-07	1.83e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—breast cancer	2.43e-07	1.83e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—breast cancer	2.42e-07	1.83e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—breast cancer	2.42e-07	1.82e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—breast cancer	2.41e-07	1.82e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—breast cancer	2.41e-07	1.82e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1A—breast cancer	2.4e-07	1.81e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTEN—breast cancer	2.4e-07	1.81e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—breast cancer	2.39e-07	1.81e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—breast cancer	2.38e-07	1.8e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK3—breast cancer	2.37e-07	1.79e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CB—breast cancer	2.36e-07	1.78e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP1B1—breast cancer	2.36e-07	1.78e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CAV1—breast cancer	2.35e-07	1.77e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK8—breast cancer	2.35e-07	1.77e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—breast cancer	2.34e-07	1.77e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—breast cancer	2.34e-07	1.76e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CAV1—breast cancer	2.33e-07	1.76e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—breast cancer	2.32e-07	1.75e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—breast cancer	2.31e-07	1.74e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.31e-07	1.74e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—breast cancer	2.31e-07	1.74e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—breast cancer	2.3e-07	1.74e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—breast cancer	2.3e-07	1.73e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CD—breast cancer	2.29e-07	1.73e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—breast cancer	2.29e-07	1.73e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CG—breast cancer	2.27e-07	1.71e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—breast cancer	2.26e-07	1.71e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—breast cancer	2.26e-07	1.71e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—breast cancer	2.26e-07	1.7e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—breast cancer	2.25e-07	1.7e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NCOA1—breast cancer	2.25e-07	1.7e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—breast cancer	2.24e-07	1.69e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—breast cancer	2.24e-07	1.69e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SRC—breast cancer	2.22e-07	1.68e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.22e-07	1.68e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—breast cancer	2.22e-07	1.67e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—STK11—breast cancer	2.21e-07	1.67e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP19A1—breast cancer	2.21e-07	1.67e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—breast cancer	2.19e-07	1.65e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—breast cancer	2.17e-07	1.63e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—breast cancer	2.17e-07	1.63e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NOS3—breast cancer	2.16e-07	1.63e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—breast cancer	2.15e-07	1.62e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—breast cancer	2.14e-07	1.61e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CG—breast cancer	2.14e-07	1.61e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—breast cancer	2.14e-07	1.61e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—breast cancer	2.13e-07	1.61e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CG—breast cancer	2.12e-07	1.6e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—breast cancer	2.11e-07	1.59e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—breast cancer	2.07e-07	1.56e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—breast cancer	2.06e-07	1.56e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—COMT—breast cancer	2.06e-07	1.55e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK3—breast cancer	2.05e-07	1.55e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTP1—breast cancer	2.05e-07	1.55e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—breast cancer	2.04e-07	1.54e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTEN—breast cancer	2.04e-07	1.54e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—HMOX1—breast cancer	2.02e-07	1.52e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—breast cancer	2.02e-07	1.52e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ITPR1—breast cancer	2.02e-07	1.52e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—breast cancer	2e-07	1.51e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CB—breast cancer	2e-07	1.51e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CD—breast cancer	2e-07	1.51e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—breast cancer	1.99e-07	1.5e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—breast cancer	1.99e-07	1.5e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—breast cancer	1.98e-07	1.49e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—breast cancer	1.97e-07	1.49e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—breast cancer	1.97e-07	1.49e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—breast cancer	1.96e-07	1.48e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—breast cancer	1.96e-07	1.48e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—breast cancer	1.95e-07	1.47e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—breast cancer	1.95e-07	1.47e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCB1—breast cancer	1.94e-07	1.46e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—breast cancer	1.91e-07	1.44e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—breast cancer	1.91e-07	1.44e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TYMS—breast cancer	1.91e-07	1.44e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—breast cancer	1.89e-07	1.43e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—breast cancer	1.89e-07	1.42e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NOS3—breast cancer	1.88e-07	1.42e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.88e-07	1.42e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTM1—breast cancer	1.88e-07	1.42e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NCOR1—breast cancer	1.88e-07	1.42e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CD—breast cancer	1.88e-07	1.42e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—breast cancer	1.87e-07	1.41e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CD—breast cancer	1.86e-07	1.41e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—breast cancer	1.86e-07	1.4e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—breast cancer	1.84e-07	1.39e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—breast cancer	1.84e-07	1.39e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—breast cancer	1.83e-07	1.38e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—breast cancer	1.81e-07	1.37e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GPX1—breast cancer	1.8e-07	1.36e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP1A1—breast cancer	1.79e-07	1.35e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NOS3—breast cancer	1.78e-07	1.34e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ERCC2—breast cancer	1.77e-07	1.34e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NOS3—breast cancer	1.76e-07	1.33e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CB—breast cancer	1.74e-07	1.31e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—breast cancer	1.73e-07	1.31e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTEN—breast cancer	1.72e-07	1.3e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—breast cancer	1.72e-07	1.3e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—breast cancer	1.72e-07	1.3e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—breast cancer	1.69e-07	1.28e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—breast cancer	1.69e-07	1.27e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—MTHFR—breast cancer	1.66e-07	1.26e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CB—breast cancer	1.64e-07	1.24e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—breast cancer	1.64e-07	1.24e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CB—breast cancer	1.62e-07	1.23e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—breast cancer	1.62e-07	1.23e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—breast cancer	1.61e-07	1.21e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—breast cancer	1.6e-07	1.21e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—breast cancer	1.6e-07	1.21e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—breast cancer	1.57e-07	1.18e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAV1—breast cancer	1.54e-07	1.16e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTEN—breast cancer	1.5e-07	1.13e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—breast cancer	1.5e-07	1.13e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—breast cancer	1.44e-07	1.08e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTEN—breast cancer	1.42e-07	1.07e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTEN—breast cancer	1.4e-07	1.06e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CG—breast cancer	1.4e-07	1.05e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—breast cancer	1.38e-07	1.04e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CD—breast cancer	1.23e-07	9.27e-07	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—breast cancer	1.22e-07	9.18e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—breast cancer	1.21e-07	9.16e-07	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—breast cancer	1.17e-07	8.86e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NOS3—breast cancer	1.16e-07	8.76e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CB—breast cancer	1.07e-07	8.08e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—breast cancer	1.06e-07	8.01e-07	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—breast cancer	1.06e-07	8e-07	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—breast cancer	9.99e-08	7.54e-07	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—breast cancer	9.94e-08	7.5e-07	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—breast cancer	9.9e-08	7.47e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTEN—breast cancer	9.26e-08	6.99e-07	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—breast cancer	8.66e-08	6.53e-07	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—breast cancer	8.16e-08	6.16e-07	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—breast cancer	8.09e-08	6.1e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—breast cancer	6.53e-08	4.93e-07	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—breast cancer	5.34e-08	4.03e-07	CbGpPWpGaD
